Genetic variations as predictors of outcome and toxicity in non-small-cell lung cancer patients undergoing chemoradiation or chemotherapy with platinum agents.

Completed

• Conditions: lung cancer; Non-small-cell lung cancer; 10027656; 10029107

• Registration Number: NL-OMON47255
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 350

Inclusion Criteria

* Diagnosed with NSCLC (stage II-IV)
* Age *18 year
* Received or starting with chemoradiation or chemotherapy with platinating agents (carboplatin, cisplatin)

Exclusion Criteria

* Unable to give informed consent
* Patients with cognitive impairment or those who are not able to read or write Dutch (because of difficulties in completing questionnaires)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Esophagitis (grade 1-4), nephrotoxicity (grade 1-4), neurotoxicity (grade 1-4)<br /><br>and genetic markers. All toxicities will be graded according to *National<br /><br>Cancer Institute Common Terminology Criteria for Adverse Events* (NCI CTCAE),<br /><br>v4.0. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Survival time is defined as survival from date of diagnosis in months. Besides,<br /><br>patient-reported outcomes and quality of life will be compared at 4 points in<br /><br>time (before treatment, after 3 months of treatment, after 6 months and 1 year<br /><br>follow-up). Skeletel muscle mass measured on available (PET)CT scans. </p><br>